These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3342412

  • 1. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J, Deere M.
    Cancer Res; 1988 Mar 01; 48(5):1337-42. PubMed ID: 3342412
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Mar 01; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 3. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG.
    Cancer Res; 1982 May 01; 42(5):1736-9. PubMed ID: 6896013
    [Abstract] [Full Text] [Related]

  • 4. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S.
    Leukemia; 1991 Nov 01; 5(11):991-8. PubMed ID: 1961042
    [Abstract] [Full Text] [Related]

  • 5. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W, Hession C, Soricelli A, Scully K.
    Cancer Treat Rep; 1977 Oct 01; 61(7):1355-64. PubMed ID: 589601
    [Abstract] [Full Text] [Related]

  • 6. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W, Woodcock TM, Gordon CS, Krakoff IH.
    Cancer Treat Rep; 1977 Oct 01; 61(7):1347-53. PubMed ID: 589600
    [Abstract] [Full Text] [Related]

  • 7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R.
    Cancer Res; 1989 Jan 01; 49(1):241-7. PubMed ID: 2908850
    [Abstract] [Full Text] [Related]

  • 9. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
    Wan CW, Mak TW.
    Cancer Res; 1979 Oct 01; 39(10):3981-5. PubMed ID: 476637
    [Abstract] [Full Text] [Related]

  • 10. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
    Wong PP, Currie VE, Mackey RW, Krakoff IH, Tan CT, Burchenal JH, Young CW.
    Cancer Treat Rep; 1979 Aug 01; 63(8):1245-9. PubMed ID: 383291
    [Abstract] [Full Text] [Related]

  • 11. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T.
    Cancer Res; 1994 Jan 01; 54(1):109-13. PubMed ID: 8261429
    [Abstract] [Full Text] [Related]

  • 13. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 01; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 14. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE, Plunkett W, Linker CA.
    Cancer Res; 1991 Aug 15; 51(16):4141-5. PubMed ID: 1868435
    [Abstract] [Full Text] [Related]

  • 15. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 16. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B, Capizzi RL, Kute TE, Morgan T, Dimling J.
    Cancer Res; 1989 Jun 15; 49(12):3259-66. PubMed ID: 2720678
    [Abstract] [Full Text] [Related]

  • 17. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 15; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 20. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
    Riva C, Barra Y, Carcassonne Y, Cano JP, Rustum Y.
    Chemotherapy; 1992 May 15; 38(5):358-66. PubMed ID: 1286578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.